APDN - Applied DNA Sciences, Inc.
| Previous Close | 1.0000 |
| Open | 1.0200 |
| Bid | 0.60 x 1000 |
| Ask | 0.90 x 900 |
| Day's Range | 0.8585 - 1.0200 |
| 52 Week Range | 0.8585 - 2.6800 |
| Volume | 311,932 |
| Avg. Volume | 156,255 |
| Market Cap | 27.101M |
| Beta (3Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
- Associated Press•3 days ago
Applied DNA Sciences: Fiscal 4Q Earnings Snapshot
The Stony Brook, New York-based company said it had a loss of 12 cents per share. The DNA-based security technology company posted revenue of $1.2 million in the period. For the year, the company reported ...
- Business Wire•3 days ago
Applied DNA Announces Selected Preliminary Unaudited Fiscal 2018 Year End and Fourth Quarter Financial Results
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the "Company"), a leader in large-scale PCR-based DNA manufacturing, announced selected preliminary unaudited financial results for the full fiscal year and quarter ended September 30, 2018. Revenues for fiscal 2018 totaled $3.9 million, a decrease of 18% from $4.8 million from the same period in the prior fiscal year. The decrease in revenues was attributable to a decrease in revenues of approximately $2.2 million in the textile industry for protecting cotton and synthetic supply chains. This decrease was offset by an increase in revenue from Contract Manufacturing of DNA for diagnostics as well as an increase from development projects, primarily those associated with partners’ pre-commercial business initiatives in legal cannabis and pharmaceuticals.
- Business Wire•6 days ago
Applied DNA Signs Joint Development Agreement with Everledger to Develop and Market a CertainT®-Enhanced, Blockchain-Based Platform for Provenance Verification
Applied DNA Sciences Inc. (APDN) (“Applied DNA,” “the Company”), a leader in large-scale PCR-based DNA manufacturing, announced today the signing of a Joint Development Agreement (the “Agreement”) with Everledger, Inc. (“Everledger”), an independent emerging technology enterprise. Under the Agreement the parties will develop and market a combined physical and digital supply chain traceability and certification solution utilizing the Company’s CertainT molecular tagging and authentication systems together with Everledger’s blockchain-based platform. The parties believe this joint solution platform is at the forefront of linking immutable digital transactions with synthetic molecular authentication to tightly track movement and chain of custody of forensically-identified goods across complex ecosystems.
- Business Wire•10 days ago
Applied DNA to Participate at Cannabis Capital Forum on December 7
Applied DNA Sciences, Inc. , the leader in large-scale PCR-based DNA manufacturing, today announced that Dr. James Hayward, president & CEO, will present at the Long Island Capital Alliance’s Cannabis Capital Forum in Melville, N.Y., on Friday, December 7 at 9:00 AM ET.
- Business Wire•12 days ago
LineaRx to Hold Analyst Day Webinar to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T Therapy
Management to Address the Potentially Critical Role of Its Platform in the Future of Gene Therapy, Vaccines and Adoptive Cell Therapies; Webinar Scheduled for December 6, 2018, 12:
- Simply Wall St.•15 days ago
What Type Of Shareholder Owns Applied DNA Sciences Inc’s (NASDAQ:APDN)?
If you want to know who really controls Applied DNA Sciences Inc (NASDAQ:APDN), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock Read More...
- Business Wire•20 days ago
Applied DNA’s SigNature® DNA Evidence Helps to Convict Over 131 Criminals to Date
Applied DNA Sciences Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, is pleased to report that SigNature DNA evidence has resulted in over 131 convictions, with sentences of 625 years to date, and many more cases in the pipeline. The confirmed number of convictions and sentencing are received from law enforcement officers. The crimes we help solve with the aid of our SigNature DNA products include attacks against armored car companies, whose activity is commonly known across Europe as “Cash-and-Valuables-in-Transit.” Other types of crimes whose conviction benefits from Applied DNA’s technology include theft of entire vehicles and their components, Automated Teller Machine (ATM) burglary, and theft of goods from businesses and private residences.
- ACCESSWIRE•25 days ago
Long Island Capital Alliance to Hold Cannabis Capital Forum on December 7, 2018
MELVILLE, NY / ACCESSWIRE / November 21, 2018 / The Long Island Capital Alliance (''LICA''), Long Island's leading non-profit capital formation and business development organization, today announced the program for its Cannabis Capital Forum to be held on Friday, December 7, 2018, including the keynote speakers, presenting companies and investor and industry panelists.
- Business Wire•27 days ago
Applied DNA and Eurofins BLC Sign Collaboration Agreement to Support Commercial Implementation of Leather Traceability System
Applied DNA Sciences Inc. (NASDAQ:APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the signing of a Collaboration Agreement (the “Agreement”) with Eurofins BLC Leather Technology Center LTD (“BLC”) to support the commercial implementation of Applied DNA’s SigNature® T-based leather traceability system (the “System”). Tony Benson, Applied DNA’s Managing Director with responsibility for Europe, Middle East and Africa (EMEA) commented, “We are thrilled to enter into this mutually beneficial relationship with BLC to advance the commercial implementation of our leather tagging system. Dr. James Hayward president and CEO of Applied DNA stated, “This agreement with BLC significantly enhances our position for the commercial implementation of our leather tagging system.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Red Lion Hotels, P.A.M. Transportation Services, Champions Oncology, Kingstone Companies, Applied DNA Sciences, and Innodata — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•last month
Applied DNA Subsidiary LineaRx Provides Cost and Quality Advantages to Technogenetics Diagnostic Solutions
Applied DNA Sciences Inc. (APDN) (“Applied DNA”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx” or the “Company”) has been providing linear DNA to Technogenetics (Shanghai Kehua Bio-Engineering Co., Ltd-KHB group) that produces and sells kits to detect autoimmunity and infectious diseases. The purified, PCR-produced DNA is custom-made for Technogenetics and is used to prepare the basic component responsible for the diagnostic specificity of two kits: one kit is used for the determination of dsDNA autoantibodies and the other for an ANA (Anti-Nuclear Antibodies) Screen. “During the kits’ development, the Technogenetics R&D laboratories tested several polynucleotides.
- Business Wire•last month
New Study: DNA Molecular Tagging is an Effective Tool to Authenticate Denim, One of the Toughest Fabrics
Results of a new study published in the September/October 2018 issue of the AATCC Review confirmed that DNA molecular tagging is an effective tool to authenticate denim and maintains its integrity even after exposed to the rigors of bleaching and abrasion. The study was conducted by: Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), and the Fashion Institute of Technology (FIT). It was published in the AATCC Review, a highly regarded publication of the American Association of Textile Chemists and Colors.
- Business Wire•2 months ago
GHCL, a Global Home Textiles Player, Creates “CIRKULARITY”, a Brand Platform, Inspired By “REKOOP” Sustainable, Traceable, Recycled Polyester Bedding
Global manufacturer of home textiles GHCL, Limited (listed on NSE and BSE) launched CIRKULARITY™, a new brand of eight lines of bedding supporting the circular economy in September, at the New York home fashions market week. REKOOP®, the inspiration behind CIRKULARITY, is a brand of bedding products made from recycled plastic (rPET) and is the first bedding product to use the Applied DNA Sciences (“Applied DNA,” “the Company,” NASDAQ: APDN) CertainT® platform.
- Business Wire•2 months ago
Applied DNA Enters FY2019 with Strong Business Momentum
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, has entered its FY2019 with strong momentum in the first month in textiles, food-based agriculture and through the LineaRx subsidiary. Textiles business expansion includes a shipment of taggant for the upland Delta cotton variety in the current 2018-2019 ginning season, two new pilots for the Company’s CertainT® system in synthetic textiles (following one additional customer pilot completed in September) and one new feasibility study for the tagging of a food-based agricultural commodity. LineaRx, the Company’s wholly-owned subsidiary focused on next-generation biotherapeutics, received a new order for PCR-produced DNA for biotherapeutic application(s).
- Business Wire•2 months ago
Applied DNA Subsidiary LineaRx Licenses CAR T Drug Candidate and Initiates Pre-Clinical Development of Non-Viral, Plasmid-Free CAR T Manufacturing Platform
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has initiated pre-clinical development of a non-viral, plasmid-free (NVPF) chimeric antigen receptor (CAR) modified T cell (CAR T) manufacturing platform which will be made available to CAR T developers worldwide. Concurrently, LineaRx announced the signing of an exclusive North American licensing agreement and research services agreement with iCell Gene Therapeutics, Inc. (iCell) under which iCell licensed to LineaRx an anti-CD19 CAR T therapy for non-viral delivery.
- Business Wire•2 months ago
Applied DNA Appoints Industry Veteran Wayne Buchen Vice President of Strategic Sales for Textile Vertical
Applied DNA Sciences Inc. (APDN) (“Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, today announced that it has appointed Wayne Buchen as Vice President of Strategic Sales, effective immediately, to lead the Company’s global textile Strategic Sales efforts. With over 20 years of sales, sourcing and operations experience with established international brands, Buchen will drive the development and execution of sales strategies to expand Applied DNA’s presence across global textile markets. Mr. Buchen most recently served as Senior Vice President of Global Sourcing and Operations for Lacoste in Hong Kong and Senior Vice President of Global Sourcing in New York.
- Business Wire•2 months ago
LineaRx Secures New RNA Therapeutics Customers for Contract Research Services
Applied DNA Sciences Inc. (APDN) (“Applied DNA), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx” ” or the “Company”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has secured multiple new developers of RNA therapeutics as customers for its Contract Research Organization (CRO) services, utilizing large scale production of linear DNA by Polymerase Chain Reaction (PCR). LineaRx provides these clients a faster, safer and less expensive manufacturing approach for these important biotherapeutics as compared to traditional production methods. As part of its recent formation, LineaRx subsumed the activities of Applied DNA as a CRO and Contract Manufacturing Organization (CMO) to the biotherapeutics market.
- Business Wire•3 months ago
Applied DNA Expands Cannabis Tagging Portfolio to Address Large Growers
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”) announced today that it is launching an additional system to tag the industry’s larger volume cannabis or hemp grows as part of TheraCann International’s ETCH Biotrace™ solution. The Company’s laboratory services and in-field testing systems round out the solution to support claims of traceability, quality and intellectual properties surrounding a cannabis brand. “The tremendous interest that came following the show has really accelerated our expansion of tagging solutions to meet the varied cannabis market conditions, including size of grower, indoor, outdoor or hybrid grow, or even the size of plant(s) that justifies the expansion of our tagging equipment solutions,” said Gordon Hope, Director of Cannabis Business Development at Applied DNA Sciences.
- Business Wire•3 months ago
Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis S.R.L. and Evvivax S.R.L. (“Takis/Evvivax”), biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively. Under the terms of the Agreement, LineaRx and Takis/Evvivax will jointly develop linear DNA expression vectors for two of Takis/Evvivax’s anti-cancer vaccine candidates utilizing LineaRx’s linear DNA technology.
- Business Wire•3 months ago
Applied DNA Forms Wholly Owned Subsidiary, LineaRx, to Develop Large-Scale, PCR-Produced DNA for Biotherapeutics
Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the formation of LineaRx, Inc., a wholly owned subsidiary. Its purpose is to commercialize the Company’s extensive experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”) in the field of biotherapeutics, specifically gene and cellular therapies as well as vaccines. The Company believes that the opportunity and markets for these biotherapeutics are substantial, and that its proprietary PCR technology offers the potential for improved outcomes relative to current plasmid and viral vector production technologies.
- Business Wire•3 months ago
Applied DNA Executes New Two-Year Contract with the U.S. Defense Logistics Agency
Applied DNA Sciences Inc., (NASDAQ:APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, announced today the signing of a new contract to continue uninterrupted service of the Company’s DNA marking program at the Defense Logistics Agency’s (DLA) Land and Maritime’s Product Test Center (PTC) in Columbus, Ohio. The contract outlines the Company’s provision of supplies and services, including creation of unique DNA marks in various inks, QC authentication testing and training. “We appreciate the DLA’s continuing support of our taggant technology platform in extending this contract for the marking of system-critical microcircuits,” stated Janice Meraglia, Vice President of Government and Military Programs at Applied DNA.
- Business Wire•3 months ago
Applied DNA Announces $1.65 Million Private Placement of Secured Convertible Notes
Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, today announced the closing in the amount of $1.65 million of secured convertible notes (the “Notes”) by way of a non-brokered private placement with accredited investors and certain members of its management team and Board of Directors, led by its Chairman, President and Chief Executive Officer. The Company expects to use the proceeds for general corporate purposes. Having demonstrated success in penetrating large and developing markets with substantial issues with supply chain security, such as the U.S. cotton supply chain, our growing penetration of non-commodity markets offer a path to revenue growth,” said Dr. James A. Hayward, chairman, president and chief executive officer of Applied DNA.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of APDN earnings conference call or presentation 13-Aug-18 8:30pm GMT
Q3 2018 Applied DNA Sciences Inc Earnings Call
- Business Wire•4 months ago
Applied DNA Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit
High-Expression Amplicons Facilitate Non-Recombinant Gene Therapies. Hold the Potential to Serve as an Alternative to Plasmids and Viral Vectors. Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, will present a poster entitled “Linear DNA High-Expression Amplicons (HEAs) for Gene Therapy” at the 6th Annual Immuno-Oncology Summit in Boston at the Seaport World Trade Center, August 28-30, 2018.
- Associated Press•4 months ago
Applied DNA Sciences: Fiscal 3Q Earnings Snapshot
The Stony Brook, New York-based company said it had a loss of 10 cents per share. The DNA-based security technology company posted revenue of $1 million in the period. In the final minutes of trading on ...
